knowledge -WSS

knowledge

author：focus 2025-10-02 04:26:22 Page View：733

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Studies point to risks of excluding people with obesity from drug trials
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

comprehensive

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

STAT Summit: Biotech founders on deal

Fromleft,EliLilly'sJacobS.VanNaarden,Avenzo'sAthenaCountouriotis,andBiohaven'sVladCoriconstageatthe2

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Lawmakers consider Medicare pay reforms for doctors

HouseEnergyandCommerceCommitteeChairCathyMcMorrisRodgers(R-Wash).J.ScottApplewhite/APWASHINGTON—TheH

knowledge

Wikipedia

comprehensive

Lawmakers consider Medicare pay reforms for doctors